| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthenia | D001247 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kwon Y et al. | Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report. | 2016 | Chest | pmid:27055712 |
| Martin M et al. | Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. | 2016 | Ann. Oncol. | pmid:27052654 |
| Coiffier B et al. | A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. | 2016 | Br. J. Haematol. | pmid:27010483 |
| Frenel JS et al. | [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]. | 2016 | Bull Cancer | pmid:26992855 |
| Sibaud V et al. | T-DM1 extravasation: first description. | 2016 | J Eur Acad Dermatol Venereol | pmid:25879278 |
| Li JY et al. | A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. | 2016 | Cancer Cell | pmid:26766593 |
| Catcott KC et al. | Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. | 2016 | MAbs | pmid:26752675 |
| Yan H et al. | Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. | 2016 | Mol. Cancer Ther. | pmid:26712117 |
| Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. | 2016 | Cancer Discov | pmid:26701087 | |
| T-DM1 Extends Survival in HER2+ Breast Cancer. | 2016 | Cancer Discov | pmid:26676162 |